Evidence map›Paper›PMID 37190889›Full record

ArticleJournal of Zhejiang University. Science. B2023

Dichloroacetic acid and rapamycin synergistically inhibit tumor progression.

Huan Chen, Kunming Liang, Cong Hou, Hai-Long Piao

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Zhejiang University. Science. B, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Dichloroacetate for Cancer Treatment: Some Facts and Many Doubts.Pharmaceuticals (Basel, Switzerland) · 2024
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Huan ChenCAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China.
Kunming LiangDepartment of Biochemistry & Molecular Biology, School of Life Sciences, China Medical University, Shenyang 110122, China.
Cong HouCAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China.
Hai-Long PiaoCAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China. hpiao@dicp.ac.cn.
Dalian Institute of Chemical Physics · CNChina Medical University · CN

Funding

the Dalian Science and Technology Innovation Funding 2019J12SN52the Liaoning Revitalization Talents Program XLYC2002035the National Key Research and Development Program of China 2022YFA0806503the National Natural Science Foundation of China 81972625
6 · The paper itself

Abstract

Mammalian target of rapamycin (mTOR) controls cellular anabolism, and mTOR signaling is hyperactive in most cancer cells. As a result, inhibition of mTOR signaling benefits cancer patients. Rapamycin is a US Food and Drug Administration (FDA)-approved drug, a specific mTOR complex 1 (mTORC1) inhibitor, for the treatment of several different types of cancer. However, rapamycin is reported to inhibit cancer growth rather than induce apoptosis. Pyruvate dehydrogenase complex (PDHc) is the gatekeeper for mitochondrial pyruvate oxidation. PDHc inactivation has been observed in a number of cancer cells, and this alteration protects cancer cells from senescence and nicotinamide adenine dinucleotide (NAD

Indexed as

NeoplasmsSirolimusDichloroacetic AcidHumansMechanistic Target of Rapamycin Complex 1Pyruvate Dehydrogenase ComplexTOR Serine-Threonine KinasesDichloroacetic AcidMechanistic Target of Rapamycin Complex 1Pyruvate Dehydrogenase ComplexSirolimusTOR Serine-Threonine KinasesDichloroacetic acid (DCA)Mammalian target of rapamycin (mTOR)Pyruvate dehydrogenase E1 subunit alpha 1 (PDHA1)Rapamycin

Identifiers

PMID37190889
PMCPMC10186139
OpenAlexW4376643239

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.